StentexStentex, a joint venture between the Renova Group and Medtronic, a global leader in medical technology, is a largest localization project in the Russian medical technology industry. The project implies the staged transfer of Medtronic’s key manufacturing technologies and complete localization of the quality system for the product line of high-tech coronary stents and catheters with proven clinical efficacy.
Stentex aims to completely satisfy the Russian healthcare system needs for world-class medical devices for treatment of patients with acute coronary syndrome (ACS), a condition that includes myocardial infarction and unstable angina.
Upon reaching its full capacity, Stentex manufacturing facility will provide more than 160,000 ACS patients with state-of-the-art medical devices per year; approximately 700 engineering, manufacturing, and business professionals will be employed in the new Stentex facility.
Along with the transfer of key manufacturing technologies, the company is focused on creating an infrastructure for preclinical studies, organizing the monitoring of clinical effectiveness of the localized medical devices, and providing educational programs for healthcare professionals.
The Company CEO is Egor Lukyanov.
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.